article
Drug approval roundup – May/June 2024
This article highlights some of the key regulatory approvals granted in May and June in the EU and US so far this year, including for oligonucleotide and biologic therapies.
List view / Grid view
paclitaxel
news
Novel device opens blood-brain barrier to deliver chemotherapy
A novel ultrasound technique opened the blood-brain barrier to successfully deliver chemotherapy to glioblastoma patients in a first-in-human trial.
news
Pembrolizumab plus chemo improves endometrial cancer survival
An interim analysis of a Phase III trial showed pembrolizumab plus chemotherapy significantly improved survival in endometrial cancer.
article
Solving the taxing problems of taxanes?
4 November 2022 | By
Could the new wave of taxane chemotherapies succeed where traditional chemotherapies have failed? Colin Freund, Chief Executive Officer of Modra Pharmaceuticals, reveals the benefits of this emerging generation of anticancer treatment.
article
Merck’s Keytruda®: update on trials and outcomes
EPR’s Anna Begley summarises some of the key results from trials of Merck’s Keytruda® (pembrolizumab) cancer treatment.
news
QUZYTTIR™ shows promise in preventing infusion related reactions
Phase II data suggests intravenous QUZYTTIR™ cetirizine hydrochloride can decrease infusion reactions to anti-CD20 antibody treatments and reduce time to discharge after therapy.
news
FDA grants Orphan Drug Designation to two cancer treatments
The FDA has given small molecules APG-115 and APG-1252, two cancer treatments, Orphan Drug Designation.
article
Polyelectrolyte multilayering: an emerging class of carriers for therapeutic agents
Polyelectrolyte multilayers (PEMs) are promising drug carriers with potential applications in the delivery of poorly soluble drugs. In this article, Sumayah Abdul-Jabbar and Paul Royall discuss the approaches for PEM construction and drug release and detail several applications of multilayered particles in therapeutics.
news
New system delivers drug straight into tumours with fewer side effects
A new drug delivery system disguises chemo-therapeutics as fat in order to destroy tumours.
news
Chemotherapy could lead to mitochondrial dysfunction in skeletal muscle
Chemotherapy drugs commonly used in breast cancer leads to a decrease in muscle mitochondria, and could result in fatigue after treatment...
